<DOC>
	<DOCNO>NCT02268175</DOCNO>
	<brief_summary>This study compare effectiveness enzalutamide without abiraterone acetate men high-risk , localized prostate cancer .</brief_summary>
	<brief_title>Enzalutamide/Leuprolide +/- Abiraterone/Pred Prostate</brief_title>
	<detailed_description>In research study , investigator compare effectiveness enzalutamide without abiraterone acetate men high-risk , localized prostate cancer . Abiraterone acetate prednisone enzalutamide currently FDA-approved use treatment patient metastatic castration-resistant prostate cancer , however investigational treatment localized prostate cancer . Abiraterone acetate work decrease production male sex hormone , cause prostate cancer growth . Enzalutamide work block effect male sex hormone , cause prostate cancer growth . The FDA ( U.S. Food Drug Administration ) approve combination enzalutamide abiraterone acetate neoadjuvant therapy high risk prostate cancer undergo prostatectomy drug approve treatment advanced prostate cancer . Participants randomize one two study arm . Randomization mean participant put group chance . It like flip coin . Neither participant research doctor choose group participant randomize . The name study medication involve study : - Enzalutamide - Abiraterone Acetate - Prednisone - Leuprolide Acetate</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Male great equal 18 year age . Histologically confirm adenocarcinoma prostate without histological variant ( include overt neuroendocrine differentiation , small cell neuroendocrine carcinoma feature , sarcomatoid feature , pure ductal adenocarcinoma , squamous transitional cell carcinoma ) . Must tissue available pretreatment diagnostic biopsy ( tissue block possible ; possible , 10 unstained slide positive core sample total 30 slide ) . Must three core biopsy involve cancer ( minimum 6 core biopsy must obtain ) . Prostate biopsy must within three month screen . Participants must follow feature : Intermediaterisk disease define Gleason 4+3=7 disease OR Highrisk disease define Gleason 810 OR PSA &gt; 20 ng/dL OR T3 disease ( prostate MRI ) No evidence metastatic nodal disease determine radionuclide bone scan CT/MRI . Participants must candidate RP consider surgically resectable urologic evaluation . ECOG performance status 0 1 ( Appendix A ) . Participants must normal organ marrow function define : WBC ≥ 3,000/mcL ANC ≥ 1,500/mcL Platelets ≥ 100,000/mcL Serum potassium ≥ 3.5 mmol/L AST , ALT , total bilirubin ≤ 1.5 x Institutional ULN Calculated creatinine clearance ≥ 60 mL/min PTT ≤ 60 , INR ≤ 1.5 x Institutional ULN unless warfarin therapy ( investigator would need determine safe participant stop warfarin prior biopsy warfarin therapy ) Controlled blood pressure define systolic blood pressure ≤ 140 mmHg diastolic blood pressure ≤ 90 mmHg three antihypertensive agent . Drug formulation contain two antihypertensive agent count base number active agent formulation . Prior hormone therapy prostate cancer include orchiectomy , antiandrogens ( include firstgeneration antiandrogens , enzalutamide , ARN509 others ) , CYP17 inhibitor ( include abiraterone , TAK700 , galeterone , ketoconazole , others ) , estrogens , LHRH agonist/antagonists . Prior therapy 5αreductace inhibitor allow . LHRH therapy allow begin within 4 week day 1 . Prior chemotherapy , radiation therapy , immunotherapy prostate cancer . Prior systemic treatment azole drug within four week screen visit . Hypogonadism severe androgen deficiency define screen serum testosterone &lt; 200 ng/dL . Clinically significant cardiovascular disease include : Acute coronary syndrome within 6 month screen visit ; Hypotension define systolic blood pressure &lt; 86 mmHg ; Bradycardia define heart rate &lt; 50 beat per minute , unless pharmaceutically induce thus reversible ( i.e . beta blocker ) ; Uncontrolled angina ( require escalate dos nitrate ) within 3 month screen visit ; Congestive heart failure NYHA Class III IV subject history congestive heart failure NYHA Class III IV , unless screen ECHO result leave ventricular ejection fraction ≥ 45 % ; History clinically significant ventricular arrhythmia ( e.g . ventricular tachycardia , ventricular fibrillation , torsades de pointes ) ; Prolonged correct QT interval Fridericia correction formula ( QTcF ) screen EKG &gt; 470 msec ; History Mobitz II second degree third degree heart block without permanent pacemaker place ; History seizure condition concurrent medication may predispose seizure . Thromboembolism within 6 month screen visit . Severe hepatic impairment ( ChildPugh Class C ) . Active symptomatic viral hepatitis chronic liver disease . History pituitary adrenal dysfunction . GI disorder may interfere absorption study drug . Preexisting condition warrant longterm corticosteroid use . Concomitant use medication may alter pharmacokinetics abiraterone enzalutamide . Individuals history different malignancy ineligible except follow circumstance : 1 ) individual history malignancy eligible diseasefree least 5 year deem investigator low risk recurrence malignancy , 2 ) individual follow cancer eligible diagnose treat within past 5 year : nonmuscle invasive bladder cancer , basal cell squamous cell carcinoma skin . Major surgery radiation therapy within 30 day screen .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>prostate adenocarcinoma</keyword>
	<keyword>advanced prostate cancer</keyword>
	<keyword>high risk prostate cancer</keyword>
</DOC>